Lu Wang

26.2k total citations · 3 hit papers
552 papers, 14.1k citations indexed

About

Lu Wang is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Lu Wang has authored 552 papers receiving a total of 14.1k indexed citations (citations by other indexed papers that have themselves been cited), including 193 papers in Molecular Biology, 127 papers in Pulmonary and Respiratory Medicine and 119 papers in Oncology. Recurrent topics in Lu Wang's work include Lung Cancer Treatments and Mutations (34 papers), Cancer Genomics and Diagnostics (33 papers) and Sarcoma Diagnosis and Treatment (33 papers). Lu Wang is often cited by papers focused on Lung Cancer Treatments and Mutations (34 papers), Cancer Genomics and Diagnostics (33 papers) and Sarcoma Diagnosis and Treatment (33 papers). Lu Wang collaborates with scholars based in China, United States and Canada. Lu Wang's co-authors include Marc Ladanyi, Mark G. Kris, Alexander Drilon, Stephen C. Winans, Maureen F. Zakowski, Meera Hameed, Adrienne T. Dennis, Arthur Brown, Eckhard Ficker and Maria E. Arcila and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Lu Wang

520 papers receiving 13.9k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

High-throughput genotyping by whole-genome resequencing

2009 646 citations Lu Wang et al. profile →
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma

2011 512 citations Tatsuo Ito, Lu Wang et al. profile →
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial

2016 327 citations Alexander Drilon, Maria E. Arcila et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Lu Wang	5.6k	3.6k	3.2k	1.9k	1.5k	552	14.1k
David M. Thomas	5.4k 1.0×	3.6k 1.0×	3.9k 1.2×	2.2k 1.2×	513 0.3×	301	14.9k
Alan Cantor	6.9k 1.2×	2.6k 0.7×	4.6k 1.5×	2.9k 1.5×	1.2k 0.8×	286	17.8k
Taylor Murray	3.8k 0.7×	3.3k 0.9×	4.5k 1.4×	1.9k 1.0×	840 0.6×	7	11.5k
Margaret Wrensch	5.7k 1.0×	2.2k 0.6×	2.3k 0.7×	3.2k 1.7×	2.5k 1.7×	200	15.1k
Rodney J. Scott	6.8k 1.2×	2.2k 0.6×	2.9k 0.9×	3.1k 1.6×	879 0.6×	538	16.9k
Freddie C. Hamdy	6.1k 1.1×	5.2k 1.4×	3.7k 1.2×	3.2k 1.6×	606 0.4×	424	15.3k
Justin Stebbing	4.3k 0.8×	2.1k 0.6×	6.1k 1.9×	3.5k 1.8×	2.1k 1.4×	524	14.8k
Agnès Viale	12.1k 2.2×	2.9k 0.8×	5.4k 1.7×	3.9k 2.0×	1.3k 0.9×	139	20.7k
Judith D. Goldberg	2.4k 0.4×	2.4k 0.7×	2.2k 0.7×	1.4k 0.7×	1.5k 1.0×	397	16.0k
Gregory H. Reaman	4.2k 0.8×	2.1k 0.6×	3.6k 1.1×	1.1k 0.5×	1.1k 0.7×	306	15.8k

Countries citing papers authored by Lu Wang

Since Specialization

Citations

This map shows the geographic impact of Lu Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lu Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lu Wang more than expected).

Fields of papers citing papers by Lu Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lu Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lu Wang. The network helps show where Lu Wang may publish in the future.

Co-authorship network of co-authors of Lu Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Lu Wang. A scholar is included among the top collaborators of Lu Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lu Wang. Lu Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shi, Jing, Fangfang Li, Aijia Wen, et al.. (2021). Structural basis of transcription activation by the global regulator Spx. Nucleic Acids Research. 49(18). 10756–10769. 20 indexed citations

Zhao, Zibo, Hiam Abdala‐Valencia, Young Ah Goo, et al.. (2021). PAX9 Determines Epigenetic State Transition and Cell Fate in Cancer. Cancer Research. 81(18). 4696–4708. 15 indexed citations

Yang, Yang, Lu Wang, Rui Wang, et al.. (2020). Screening of compatible maizeSNP384 markers and the construction of DNA fingerprints of maize varieties. ACTA AGRONOMICA SINICA. 46(7). 1006–1015. 2 indexed citations

Suehara, Yoshiyuki, Deepu Alex, Anita S. Bowman, et al.. (2019). Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations. Clinical Cancer Research. 25(21). 6346–6356. 98 indexed citations

Wang, Lu, et al.. (2018). The Transcription Factor AP4 Promotes Oncogenic Phenotypes and Cisplatin Resistance by Regulating LAPTM4B Expression. Molecular Cancer Research. 16(5). 857–868. 15 indexed citations

Ng, Charlotte K.Y., François‐Clément Bidard, Salvatore Piscuoglio, et al.. (2017). Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases. Clinical Cancer Research. 23(15). 4402–4415. 83 indexed citations

Ichihara, Eiki, David Westover, Catherine B. Meador, et al.. (2017). SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer. Cancer Research. 77(11). 2990–3000. 104 indexed citations

Ptashkin, Ryan, Carlos Pagan, Rona Yaeger, et al.. (2017). Chromosome 20q Amplification Defines a Subtype of Microsatellite Stable, Left-Sided Colon Cancers with Wild-type RAS/RAF and Better Overall Survival. Molecular Cancer Research. 15(6). 708–713. 19 indexed citations

Yaeger, Rona, Zhan Yao, David M. Hyman, et al.. (2017). Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. Cancer Research. 77(23). 6513–6523. 60 indexed citations

10.

Amato, Katherine, Shan Wang, Li Tan, et al.. (2016). EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer. Cancer Research. 76(2). 305–318. 84 indexed citations

11.

Dalin, Martin G., Alexis Desrichard, Nora Katabi, et al.. (2016). Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer. Clinical Cancer Research. 22(18). 4623–4633. 135 indexed citations

12.

Youngblood, Victoria, Laura C. Kim, Deanna N. Edwards, et al.. (2016). The Ephrin-A1/EPHA2 Signaling Axis Regulates Glutamine Metabolism in HER2-Positive Breast Cancer. Cancer Research. 76(7). 1825–1836. 61 indexed citations

13.

Mathias, Melissa, Alexander J. Chou, Paul A. Meyers, et al.. (2016). Osteosarcoma With Apparent Ewing Sarcoma Gene Rearrangement. Journal of Pediatric Hematology/Oncology. 38(5). e166–e168. 2 indexed citations

14.

Drilon, Alexander, Lu Wang, Maria E. Arcila, et al.. (2015). Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. Clinical Cancer Research. 21(16). 3631–3639. 202 indexed citations

15.

Drilon, Alexander, Romel Somwar, Jacob P. Wagner, et al.. (2015). A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1 -Rearranged Lung Cancer. Clinical Cancer Research. 22(10). 2351–2358. 128 indexed citations

16.

Hechtman, Jaclyn F., Ahmet Zehir, Rona Yaeger, et al.. (2015). Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF. Molecular Cancer Research. 14(3). 296–301. 43 indexed citations

17.

Meador, Catherine B., Hailing Jin, Elisa de Stanchina, et al.. (2014). Optimizing the Sequence of Anti-EGFR–Targeted Therapy in EGFR-Mutant Lung Cancer. Molecular Cancer Therapeutics. 14(2). 542–552. 22 indexed citations

18.

Suehara, Yoshiyuki, Maria E. Arcila, Lu Wang, et al.. (2012). Identification of KIF5B-RET and GOPC-ROS1 Fusions in Lung Adenocarcinomas through a Comprehensive mRNA-Based Screen for Tyrosine Kinase Fusions. Clinical Cancer Research. 18(24). 6599–6608. 132 indexed citations

19.

Su, Yingjun, Anna E. Vilgelm, Mark C. Kelley, et al.. (2012). RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors. Clinical Cancer Research. 18(8). 2184–2198. 47 indexed citations

20.

Nagathihalli, Nagaraj S., Pierre P. Massion, Adriana L. Gonzalez, Lu Wang, & Pran K. Datta. (2012). Smoking Induces Epithelial-to-Mesenchymal Transition in Non–Small Cell Lung Cancer through HDAC-Mediated Downregulation of E-Cadherin. Molecular Cancer Therapeutics. 11(11). 2362–2372. 77 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact